Gefitinib
- Generic Name
- Gefitinib
- Brand Names
- Iressa, Gefitinib Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C22H24ClFN4O3
- CAS Number
- 184475-35-2
- Unique Ingredient Identifier
- S65743JHBS
- Background
Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.
- Indication
For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer
- Associated Therapies
- -
Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study
- First Posted Date
- 2005-09-30
- Last Posted Date
- 2015-10-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 317
- Registration Number
- NCT00229697
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
Effect of Iressa With/Without Concurrent Chemoradiotherapy on Tumor Gene Expression Profiles in Patients With Advanced Non-Nasopharyngeal Head and Neck Carcinoma
- Conditions
- First Posted Date
- 2005-09-29
- Last Posted Date
- 2007-12-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT00228488
Gefitinib as First-Line Therapy Followed by Gemcitabine and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2012-06-05
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 63
- Registration Number
- NCT00217698
- Locations
- 🇨🇭
Hopital Cantonal Universitaire de Geneve, Geneva, Switzerland
🇨🇭Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
🇨🇭Klinik Hirslanden, Zurich, Switzerland
Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2011-01-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 477
- Registration Number
- NCT00206219
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature
- Conditions
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2024-03-08
- Target Recruit Count
- 90
- Registration Number
- NCT00198380
- Locations
- 🇫🇷
Centre F. Baclesse, Caen, France
🇫🇷HCL - Croix-Rousse, Lyon, France
🇫🇷APHP - CHU Avicenne - Oncologie Medicale, Bobigny, France
Randomized Phase 2 Study of 3 Therapeutic Modalities in PS 2/3 Patients With NSCLC Stage IIIB/IV
- Conditions
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2010-04-30
- Target Recruit Count
- 126
- Registration Number
- NCT00198393
- Locations
- 🇫🇷
CHU Grenoble - pneumologie, Grenoble, France
🇫🇷CHU Avicenne - Oncologie, Bobigny, France
Chemotherapy Plus Gefitinib Followed by Chemotherapy, Radiation Therapy, and Gefitinib For Head and Neck Cancer
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-06-22
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 50
- Registration Number
- NCT00193284
- Locations
- 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Phase 2 Study Of Neoadjuvant Iressa Treatment In Stage 1 NSCLC
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-03-14
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 35
- Registration Number
- NCT00188617
- Locations
- 🇨🇦
Toronto General Hospital, Toronto, Ontario, Canada
Study of Gefitinib and Docetaxel as Salvage Therapy in Advanced Pancreatic Carcinoma
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2016-01-18
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 45
- Registration Number
- NCT00177242
- Locations
- 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia
- First Posted Date
- 2005-08-16
- Last Posted Date
- 2014-05-01
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 18
- Registration Number
- NCT00130702
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.